Compare G & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | G | HALO |
|---|---|---|
| Founded | 1997 | 1998 |
| Country | Bermuda | United States |
| Employees | 140000 | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 8.8B |
| IPO Year | 2007 | 2001 |
| Metric | G | HALO |
|---|---|---|
| Price | $40.72 | $70.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 11 |
| Target Price | $49.50 | ★ $78.18 |
| AVG Volume (30 Days) | ★ 3.0M | 2.0M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.86% | N/A |
| EPS Growth | ★ 9.82 | N/A |
| EPS | ★ 3.13 | 2.56 |
| Revenue | ★ $2,279,438,000.00 | $151,862,000.00 |
| Revenue This Year | $9.23 | $28.38 |
| Revenue Next Year | $7.26 | $12.72 |
| P/E Ratio | ★ $12.93 | $27.12 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $34.79 | $47.50 |
| 52 Week High | $52.03 | $82.22 |
| Indicator | G | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 51.39 | 41.55 |
| Support Level | $37.58 | $67.94 |
| Resistance Level | $46.04 | $74.92 |
| Average True Range (ATR) | 1.26 | 2.53 |
| MACD | 0.56 | -0.79 |
| Stochastic Oscillator | 96.08 | 14.68 |
Genpact Ltd is a provider of business process management services. Clients are industry verticals and operate in banking and financial services, insurance, capital markets, consumer product goods, life sciences, infrastructure, manufacturing and services, healthcare, and high-tech. Genpact's services include aftermarket, direct procurement, risk and compliance, human resources, IT, industrial solutions, collections, finance and accounting, and media services. Genpact's end market by revenue is India. It is a General Electric spin-off, which is still a large source of revenue for Genpact.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.